Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PROTEINS FROM MAMMALIAN LIVER AND THEIR USE IN ONCOLOGY
Document Type and Number:
WIPO Patent Application WO/1996/002567
Kind Code:
A1
Abstract:
The present invention refers to proteins extractable by perchloric acid from mammalian liver, particularly from goat liver, and to their use in oncology.

Inventors:
Ronchi
Severino, Bartorelli
Alberto
Application Number:
PCT/EP1995/002723
Publication Date:
February 01, 1996
Filing Date:
July 12, 1995
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Zetesis S.
Ronchi, Severino Bartorelli Alberto
International Classes:
C12N15/02; A61K35/407; A61K38/00; A61K38/17; A61P35/00; B23K26/08; C07K14/47; C12P21/08; F01D25/28; F02C7/00; F02M25/08; F04B45/047; F23R3/60; C12R1/91; (IPC1-7): C07K14/47; A61K38/17
Domestic Patent References:
WO1992010197A1
Other References:
EUR. J. BIOCHEM. (1993), 212(3), 665-73 CODEN: EJBCAI;ISSN: 0014-2956, 1993 LEVY-FAVATIER, FLORENCE ET AL 'Characterization, purification and cDNA cloning of a rat perchloric-acid-soluble 23-kDa protein present only in liver and kidney' cited in the application
DATABASE EMBL Emrod:Rspsp1; Access-no: D49363 OKA, T. 'Sequence of PSP1'; 22 February 1995
DATABASE EMBL Emest:Hs68065, Access-no: T98680 HILLIER, L. ET AL 'The WashU-Merck EST Project'; 17 April 1995
Download PDF:
Claims:
CLAIMS
1. Proteins extractable from mammalian liver but not from rat liver having the partial aminoacid sequence of Sequence Id n. 1 or sequences having an homology degree of at least 80% with said Sequence Id n. 1.
2. Proteins according to claim 1 having an homology degree of at least 90% with said Sequence Id n. 1.
3. Proteins according to claim 1 or 2 extractable from goat, horse or calf liver.
4. Proteins according to claim 3 extractable from goat liver.
5. Proteins according to any one of the previous claims having molecular weight from about 10 to about 14 Kda.
6. Proteins according to claim 5 having molecular weight of about 14 Kda.
7. Proteins according to any one of the previous claims, recognized by the antibodies secreted from the hybridomas deposited at ECACC under numbers 930806103 and 930806104.
8. Proteins extractable from mammalian liver having the partial aminoacid sequence of Sequence Id n. 1 or sequences having an homology degree of at least 80% with said Sequence Id n. 1, for use in antitumor therapy.
9. Pharmaceutical compositions containing as the active principle the proteins of claim 1 or 8 in admixture with a suitable carrier.
10. Use of the proteins extractable from mammalian liver having the partial aminoacid sequence of Sequence Id n. 1 or sequences having an homology degree of at least 80% with said Sequence Id n. 1 in diagnostics.
Description:
PROTEINS FROM MAMMALIAN LIVER AND THEIR USE IN ONCOLOGY

The present invention refers to proteins from animal tissues, particularly from mammalian liver, and to the use thereof in oncology.

WO 92/10197 discloses extracts of mammalian organs, particularly of goat liver, consisting of at least three different proteins and characterized by unusual pharmacological and immunological properties. No information was reported on the actual role and on the sequences of the individual protein components. 23-KDa dimeric protein extracted with 5% perchloric acid from rat liver and kidney has been disclosed in Eur. J. Biochem. 272, 665, 1993. The corresponding cDNA sequence have been deposited at the EMBL data bank under accession number X70825. This protein, reported to be co-extracted with High-mobility group (HMG) proteins, is suggested to play a role in the folding of proteins, so that it could be considered as one member of the class of the so-called "chaperons" or chaperonins. WO 93/18146 discloses a protein extracted from rabbit-liver having a molecular weight of 59Kd capable of complexing with chaperons and a heat shock protein of 90 Kd.

A new protein purified from the extract disclosed in WO 92/10197, has been found now having the partial aminoacid sequence depicted in sequence Id n. 1.

Said protein is useful in oncology in view of the following properties:

the serum of animals immunized with the protein displays cytotoxic activity against human tumor cell cultures; the protein has marked antineoplastic activity at the dose of 0.015 μg/kg in Balb/c mice having a murine colon adenocarcinoma (c26) and in rats with intrapleuric Yoshida ascitic tumor; when administered to animals, man included, it raises antibodies able to recognize human carcinoma cells.

Said properties explain the activity observed in clinical tests carried out administering the extract of WO 92/10197 to patients affected by advanced cancer of the lung, breast, stomach, colon and liver. The protein of the invention has a high degree of homology with that extracted from rat liver disclosed in Eur. J. Biochem. 272, 665, 1993.

Proteins having a high degree of homology with that of Sequence Id n. 1 have also been found in liver of different animal species, particularly bovine and equine liver. The invention refers also to said homologous sequences, except the known sequence from rat liver.

A new protein family has been therefore found: the members of this previously unknown family are characterized by an high degree of conservation and homology between the mammalian species and a molecular weight ranging from about 10 KDa to about 14 KDa.

The term "high degree of homology" means an homology of the a inoacid sequences of about 80% or higher, preferably of 90% or higher.

The invention further refers to the use in oncology, as a therapeutic and/or diagnostic tool, of the above mentioned perchloric acid extractable proteins from mammalian liver. The invention provides therefore pharmaceutical compositions containing the protein having the partial amino acid sequence n. 1 or proteins having at least 80% homology, preferably at least 90% homology, with Sequence Id n. 1. The pharmaceutical compositions of the invention will be administered by parenteral route, preferably subcutaneously or intra- uscularly and will typically contain from 0.1 to 50 mg of total protein per unit dose. The protein active principle, purified by conventional methods, may be lyophilized on a suitable non-toxic carrier and distributed in vials or bottles.

Suitable solvents include sterile water or saline solutions.

According to a further embodiment of the invention, the proteins of the invention or fragments thereof, produced for instance by chemical synthesis, may be used to produce polyclonal or monoclonal antibodies. Particularly interesting antibodies recognize tumoral antigens and are therefore useful for diagnostic, therapeutic or research purposes. Two of said antibodies have been deposited on 27-7-1993 at the European collection of Animal Cell Cultures (EGACC), Porton Down, Salisbury, UK under accession numbers 930806103 and 930806104. These antibodies were used in immunocytochemical tests on several bioptic samples of human cancers,

enabling their recognition.

The proteins of the invention, when administered to patients affected by neoplastic disease, in addition to advantageous effects such as inhibition or regression of the tumoral mass, reduction of pam and improvement of cenestesis, raise antibodies having marked cytotoxic action on cultured tumor cells. The whole serum, not free from the complement cascade, is required for said cytotoxic effect. When used for therapeutic purposes or as a vaccine to induce immunity against neoplastic transformation, the proteins of the invention may be administered at a dosage ranging from 0.1 to 30 mg/day/patient, by the subcutaneous, intramuscular or intravenous route. The treatment will be repeated even for long periods, until the concentration of the raised antibodies reaches a convenient level.

The concentration of the raised antibodies may be determined by conventional methods, using for instance lmmunoenzymatic techniques. To this purpose, the invention provides diagnostic kits containing suitably labelled reagents, e.g. the protein of the invention or fragments thereof as an antigen, optionally immobilized on a suitable support, anti-Ig antibodies and suitable reagents able to detect, e.g. by means of a colorlmetric reaction, an antigen-antibody complex.

The proteins of the invention may advantageously be administered together with suitable carriers, acting as adjuvants. Suitable adjuvants may be selected, for instance, from non-toxic proteins, preferably xenogenic proteins, e.g. proteins from the same species from

which the immunogenic protein is extracted.

The proteins of the invention are prepared by subjecting the crude extract, obtained by extracting the organs with perchloric acid and subsequently with hypertonic saline solutions (KCl 3M for instance) and subsequent dialysis, to purification steps in HPLC and hydrophobic exchange chromatography (FPLC) as hereinafter specified in the Examples.

The protein obtained from goat liver is blocked at the N-terminal and it has been therefore partially sequenced after cleavage with CNBr, yielding two main fragments having molecular weight (determined by the MALDI-TOF method) respectively of 10263 and 4063 D, respectively, whereas the molecular weight before cleavage is 14.290 Daltons, in agreement with the value determined by SDS-PAGE electrophoresis.

The following examples further illustrate the invention.

Example 1 A liver goat extract, prepared as in WO 92/10197, and hereinafter referred to as UK 101, is concentrated on Amicon PM 10 membrane and subsequently dialyzed against NaH 2 P0 4 /Na 2 HP0 4 , 0.01 M, pH 6.5. The product is purified by HPLC on TSK DEAE 5 PW equilibrated in said buffer; the starting buffer is collected and the protein absorbed on the resin are eluted with 1M NaCl. The peak eluted in the starting buffer is subsequently purified by HPLC on TSK SW 3000 column.

Two main peaks are obtained by this chromatography: the first is discarded since it mainly consists of glycogen; the second, particularly rich in

low molecular weight proteins, is then purified by FPLC on Protein-Pac HIC Phenyl 5 PW column.

The purification on this hydrophobic exchange column, is carried out in the following conditions: a starting buffer, Tris HCl 20 mM pH 7 containing (NH 4 ) 2 S0 4 1M, is first eluted, followed by a linear gradient elution ending with Tris- HCl 20 mM without ammonium sulfate. The starting buffer is discarded whereas the zone, eluted in the gradient at a ( H 4 )2S0 4 molarity ranging from 0.6 to 0.8 M is collected and dialyzed against H 2 0.

A sample hereinafter referred to as UK 114 showing a protein band in SDS-PAGE of about 14 Kda with a purity degree of about 90% is obtained. Example 2

In immunocytochemical tests, polyclonal antibodies raised in rabbits immunized with liver goat extract (WO

92/10197) administered subcutaneously in PBS with

Freund's complete adjuvant every week for 2 months were used.

Monoclonal antibodies were obtained from Balb/c mice one month after weekly subcutaneous injections of 100 μg of UK 101 with incomplete Freund's adjuvant. The fusion with myeloma cells of lymphocytes obtained from animals immunized against UK 101 was carried out by conventional methods. Two of the obtained hybridomas were deposited on 27-7-1993 at the European Collection of Animal Cell Cultures (ECACC) Porton Down, Salisbury, UK, under accession numbers 930806103 and 930806104.

The antibodies secreted by said hybridome

recognize the proteins of the invention.

The mono- and polyclonal antibodies have been assayed in immunocytochemistry tests on 30 bioptic samples of malignant tumors isolated from different organs such as breast, lung, bladder, stomach, colon- rectum, uterus, soft tissues, prostate. The tissues were fixed in 10%, buffered formaline and preparations in paraffine were stained by means of Mistostain Kit SP, Zymed Lab. Inc.. The sections were incubated with the antibodies (0.5 μg/ml of Ig with 1% BSA/PBS) overnight at 4'C. After washing, the slides were incubated with anti- rabbit pig biotinylated Ig for 60 minutes and then for other 60 minutes with a 1:100 dilution of peroxidated streptavidine-biotine complex. The peroxidase binding was detected using the 3 , 3-diaminobenzidine/H 2 0 2 reaction. Only the tissue showing specific reaction against the antibodies in the cytoplasma were considered positive. The immunoreactivity was considered as negative, slightly positive, positive (++) and highly positive (+++) for the normal tissues. The results are reported in the following Table. The immunocytochemical reactivity with different polyclonal antibodies anti goat, calf and horse liver extract is detectable in most malignant tumors (82.7% for antibodies against horse liver extract and 100% for calf liver extract). The monoclonal antibody secreted by the hybrido a n. 930806103 gave positive results for 93.7% of the assayed tumors.

TABLE

Immunocytochemical reactivity of malignant tumors (+/-)

Total 25/5 14/0 13/1 15/1

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: ZETESIS (B) STREET: Galleria del Corso 2

(C) CITY: MILAN

(E) COUNTRY: ITALY

(F) POSTAL CODE (ZIP): 20122

(ii) TITLE OF INVENTION: PROTEINS FROM MAMMALIAN LIVER AND THEIR USE IN ONCOLOGY

(iii) NUMBER OF SEQUENCES: 1

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: Patentln Release #1.0, Version #1.25 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 53 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE:

(A) ORGANISM: Capra hircus (F) TISSUE TYPE: Liver

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Met Asp Pro Ala Ser Gly Gin Leu Val Pro Gly Gly Val Val 1 5 10

Glu Glu Ala Lys Gin Ala Leu Thr Asn lie Gly Glu lie Leu 15 20 25

Lys Ala Ala Gly Xaa Asp Phe Thr Asn Val Val Lys Ala Thr 30 35 40 Val Leu Leu Ala Asp lie Asn Asp Phe Xaa Ala 45 50

INTERNATIONAL FORM

TO RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the

Zetesis spa π INTERNATIONAL DEPOSITARY AUTHORITY Galleria del Corso identified at the bottom of this page

2 Milano

Italy

NAME AND ADDRESS OF DEPOSITOR

IDENTIFICATION OF THE MICROORGANISM

Identi ication reference given by the Accession number given by the DEPOSITOR: INTERNATIONAL DEPOSITARY AUTHORITY:

P3D1D11

930806103

II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism Identified under I above was accompanied by:

I I a scientific description I I a proposed taxonoaic designation

(Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism Identified under I above, which was received by it on xr -(. --. (date of the original deposit) 1

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International

Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

INTERNATIONAL DEPOSITARY AUTHORITY

Name : Signature(s) of person(s) having the power

Dr A Doyle to represent the International Depositary

ECACC Authority or of .authorized official(s):

CAMR

Address : Da e: g Ua^^^S

Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

Form BP/4 (sole page)

11

BUDAPEST TREATY ON THE INTERNATIONAL

RECOGNITION OF THE DEPOS IT OF MI CROORGANISMS

FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

VIABILITY STATEMENT Galleria del Corso iss ued pursuant to Rule 10 . 2 by the 2 Milano INTERNATIONAL DEPOSITARY AUTHORITY identified on the following page Italy

NAME AND ADDRESS OF THE PART ΓYY

TO WHOM THE VIABI LITY STATEME:NNTT

IS ISSUED

Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

I n the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability tcct.

Mark with a cross the applicable box.

Form BP/9 (first page)

I IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED

INTERNATIONAL DEPOSITARY AUTHORITY

N me: n r A Doyle Signature(s) of person(s) having the power to represent the International Depositary ECACC Authority or of authorized official(s):

Address.CAMR

Date:

S Marcr

Fill in if the information has been requested and if the results of the test were negative.

Form BP/9 (second and last page)